Construction of an immune‐related LncRNA signature with prognostic significance for bladder cancer

• Published in: Journal of cellular and molecular medicine Vol. 25; no. 9; pp. 4326 - 4339
• Main Authors: Luo, Wen‐Jie, Tian, Xi, Xu, Wen‐Hao, Qu, Yuan‐Yuan, Zhu, Wen‐Kai, Wu, Jie, Ma, Chun‐Guang, Zhang, Hai‐Liang, Ye, Ding‐Wei, Zhu, Yi‐Ping
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2021; John Wiley and Sons Inc
• Subjects: Algorithms; Apoptosis; Bladder cancer; Cancer; Cancer therapies; Cell proliferation; Gene expression; Genetic engineering; Genomics; Immune system; immunity; Immunotherapy; Invasiveness; lncRNA signature; Lymphocytes; Medical prognosis; Medical research; Original; pan‐cancers; prognosis; Software; Tumor necrosis factor-TNF; Tumors; United States > US; China; pan-cancers; immunity; prognosis; bladder cancer; lncRNA signature
• ISSN: 1582-1838; 1582-4934; 1582-4934
• DOI: 10.1111/jcmm.16494

Bladder cancer (BLCA) is one of the most common urological cancer with increasing cases and deaths every year. In the present study, we aim to construct an immune‐related prognostic lncRNA signature (IRPLS) in bladder cancer (BLCA) patients and explore its immunogenomic implications in pan‐cancers. First, the immune‐related differentially expressed lncRNAs (IRDELs) were identified by ‘limma’ R package and the score of IRPLS in every patient were evaluated by Cox regression. The dysregulation of IRDELs expression between cancer and para‐cancer normal tissues was validated through RT‐qPCR. Then, we further explore the biological functions of a novel lncRNA from IRPLS, RP11‐89 in BLCA using CCK8 assay, Transwell assay and Apoptosis analysis, which indicated that RP11‐89 was able to promote cell proliferation and invasive capacity while inhibits cell apoptosis in BLCA. In addition, we performed bioinformatic methods and RIP to investigate and validate the RP11‐89/miR‐27a‐3p/PPARγ pathway in order to explore the mechanism. Next, CIBERSORT and ESTIMATE algorithm were used to evaluate abundance of tumour‐infiltrating immune cells and scores of tumour environment elements in BLCA with different level of IRPLS risk scores. Finally, multiple bioinformatic methods were performed to show us the immune landscape of these four lncRNAs for pan‐cancers. In conclusion, this study first constructed an immune‐related prognostic lncRNA signature, which consists of RP11‐89, PSORS1C3, LINC02672 and MIR100HG and might shed lights on novel targets for individualized immunotherapy for BLCA patients.